Roquefort Therapeutics (LON:ROQ) Shares Down 3.2% – Should You Sell?

Roquefort Therapeutics plc (LON:ROQ) shares fell 3.2% on Friday . The company traded as low as GBX 1.48 and last traded at GBX 1.50. 358,800 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 2,078,175 shares. The stock had previously closed at GBX 1.55.

Roquefort Therapeutics Price Performance

The stock’s fifty day moving average price is GBX 1.94 and its two-hundred day moving average price is GBX 1.70. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The firm has a market capitalization of £2.36 million, a price-to-earnings ratio of -2.38 and a beta of 0.05.

Roquefort Therapeutics (LON:ROQ) last posted its quarterly earnings data on Tuesday, September 30th. The company reported GBX (0.33) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative return on equity of 29.57% and a negative net margin of 57,057.07%.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.